EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE ‐ JP Trial

Koutaro Yokote iD, Toshimasa Yamauchi iD, Yasushi Fukushima iD, Yoji Takatsuka iD, Marie Kato iD, Shijia Yan iD, Takayoshi Inoue iD, Luiza Borowska iD, Martina Brueckmann iD, Wataru Ogawa iD, SYNCHRONIZE‐JP Trial Investigators

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70862 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Koutaro Yokote und 10 weiteren Autor:innen. Beteiligte Einrichtung: Chiba University, Chiba, Japan. Hauptthemen laut MEDLINE: Obesity, Glucagon-Like Peptide-1 Receptor Agonists, Anti-Obesity Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist with the potential to induce greater weight reductions than GLP‐1R mono‐agonists. We report the design and baseline participant characteristics of the SYNCHRONIZE‐JP trial evaluating survodutide in Japanese adults with obesity disease ( ClinicalTrials.gov : NCT06176365). Materials and Methods SYNCHRONIZE‐JP is a 76‐week, randomised, double‐blind, parallel‐group, multi‐centre, phase 3 clinical trial. Eligible participants were aged ≥ 18 years, with BMI ≥ 35 kg/m 2 with ≥ 1 obesity complication or BMI ≥ 27 kg/m 2 with ≥ 2 obesity complications, ≥ 1 self‐reported unsuccessful dietary effort to lose body weight and ≥ 1 obesity complication required to be type 2 diabetes (T2D; capped at 30% enrolment), hypertension or dyslipidaemia. Participants were randomised 1:1:1 to receive once‐weekly survodutide 3.6 or 6.0 mg, or placebo, accompanied by a reduced‐calorie diet and increased physical activity. The primary endpoints are percentage change in body weight and achievement of body weight reduction ≥ 5% from baseline to Week 76. A subset of participants will be assessed for additional endpoints of liver fat content and body composition.

Results

Of 274 enrolled participants, 24.1% had T2D. The mean age was 53.1 years; 47.8% were female, and mean BMI was 33.2 kg/m 2 . The most frequent complications were dyslipidaemia (81.4%), hypertension (72.6%), hyperuricaemia (30.3%) and metabolic dysfunction‐associated steatotic liver disease (26.6%).

Conclusions

The results of SYNCHRONIZE‐JP will provide Japan‐specific efficacy, safety and tolerability data for survodutide and inform its potential role in the management of obesity disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityGlucagon-Like Peptide-1 Receptor AgonistsAnti-Obesity AgentsHumansFemaleDouble-Blind MethodMaleMiddle AgedJapanAdultDiabetes Mellitus, Type 2Clinical Trials, Phase III as TopicRandomized Controlled Trials as TopicMulticenter Studies as TopicWeight LossTreatment OutcomeAgedEast Asian People

Stichwörter der Autor:innen

glucagon receptor agonistglucagon‐like peptide‐1 receptor agonistobesitysurvodutidetrial design

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsAnti-Obesity Agents

Autor:innen und Institutionen

  • Chiba University, Chiba, Japan.
  • Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Fukuwa Clinic, Tokyo, Japan.
  • Motomachi Takatsuka Internal Medicine Clinic, Yokohama, Japan.
  • Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan.
  • Boehringer Ingelheim (China) Investment Co. Ltd., Shanghai, China.

ORCID-Profile: Koutaro Yokote, Toshimasa Yamauchi, Yasushi Fukushima, Yoji Takatsuka, Marie Kato, Shijia Yan, Takayoshi Inoue, Luiza Borowska, Martina Brueckmann, Wataru Ogawa

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Yokote, K., Yamauchi, T., Fukushima, Y., Takatsuka, Y., Kato, M., Yan, S., Inoue, T., Borowska, L., Brueckmann, M., Ogawa, W., & SYNCHRONIZE‐JP Trial Investigators (2026). Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE ‐ JP Trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70862

Vancouver

Yokote K, Yamauchi T, Fukushima Y, Takatsuka Y, Kato M, Yan S, et al. Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE ‐ JP Trial. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70862

BibTeX
@article{Yokote2026,
  author = {Yokote, Koutaro and Yamauchi, Toshimasa and Fukushima, Yasushi and Takatsuka, Yoji and Kato, Marie and Yan, Shijia and Inoue, Takayoshi and Borowska, Luiza and Brueckmann, Martina and Ogawa, Wataru and SYNCHRONIZE‐JP Trial Investigators, SYNCHRONIZE‐JP Trial Investigators},
  title = {Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE ‐ JP Trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70862}
}
Kostenlos starten →